Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Novocure

< Previous 1 2 3 Next >
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Tickers NVCR
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Planned CEO Transition
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
From Novocure
Via Business Wire
Tickers NVCR
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.